NTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications – a systematic review

20250 citationsJournal Articlegreen Open Access

Authors

Shahd Hamran · Qatar University

Zaineh Alnoubani · Qatar University

Ahmad Hassan · Qatar University

Amani A. Al-Rajhi · Qatar University

Humam Emad Rajha · Qatar University

Munirah Altaissan · Qatar University

Giridhara R. Babu · Qatar University

Abstract

We confirm the rarity of NTRK1-3 fusions in sarcomas. TRK inhibitors show high efficacy in sarcomas, emphasizing the necessity of genomic testing in all cases.Protocol registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024563594.

Topics & Keywords

Sarcoma Diagnosis and Treatment Lung Cancer Treatments and Mutations Melanoma and MAPK Pathways

Publication Details

Published in: Future Oncology

Volume 21, Issue 30, pp. 4011-4024

DOI: 10.1080/14796694.2025.2597405

Field-Weighted Citation Impact: 0.00

Command Palette

<i>NTRK1-3</i> fusions in sarcomas: prevalence, significance, and clinical implications – a systematic review

Authors

Abstract

Topics & Keywords

Publication Details